DGX Form 144: Planned $1.49M sale of Quest Diagnostics stock

Rhea-AI Filing Summary

Quest Diagnostics (DGX) reported a planned sale of common stock under Rule 144. The notice covers the potential sale of 7,946 common shares through Fidelity Brokerage Services on the NYSE, with an indicated aggregate market value of $1,488,683.10. These shares were acquired on 11/18/2025 by exercising stock options originally granted on 03/21/2022 (7,846 shares) and 02/23/2023 (100 shares), with payment made in cash. The filing notes that there were 111,242,362 common shares outstanding at the time referenced, giving investors context for the relative size of this planned sale.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	7946	1488683.10	111242362	11/18/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/18/2025	Option Granted - 03/21/2022	Issuer			7846	11/18/2025	Cash
Common	11/18/2025	Option Granted - 02/23/2023	Issuer			100	11/18/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for Quest Diagnostics (DGX) disclose?

The Form 144 notice for Quest Diagnostics (DGX) discloses a planned sale of 7,946 common shares of the company’s stock under Rule 144, to be executed through Fidelity Brokerage Services LLC on the NYSE.

How many Quest Diagnostics (DGX) shares are planned to be sold and what is their market value?

The filing states an intent to sell 7,946 common shares of Quest Diagnostics, with an aggregate market value of $1,488,683.10 based on the figures provided in the notice.

When were the Quest Diagnostics (DGX) shares acquired and how?

The shares were acquired on 11/18/2025 by exercising stock options originally granted on 03/21/2022 for 7,846 shares and on 02/23/2023 for 100 shares, with the exercise price paid in cash.

On which exchange will the Quest Diagnostics (DGX) shares be sold and around what date?

The notice indicates an approximate sale date of 11/18/2025, with the planned sales to occur on the NYSE through Fidelity Brokerage Services LLC.

How many Quest Diagnostics (DGX) shares were outstanding according to the Form 144 notice?

The Form 144 reports that 111,242,362 common shares of Quest Diagnostics were outstanding at the referenced time, providing context for the size of the planned 7,946-share sale.

What representations does the seller make in the Quest Diagnostics (DGX) Form 144?

By signing the notice, the seller represents that they do not know of any material adverse information about Quest Diagnostics’ current or prospective operations that has not been publicly disclosed, and this representation also applies as of any disclosed Rule 10b5-1 plan adoption date.